Spruce Biosciences, Inc.
General ticker "SPRB" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $30.1M (TTM average)
Spruce Biosciences, Inc. follows the US Stock Market performance with the rate: 9.4%.
Estimated limits based on current volatility of 3.7%: low 43.39$, high 46.72$
Factors to consider:
- Total employees count: 8 (-61.9%) as of 2025
- Top business risk factors: Insufficient capital, Clinical trial failure, Regulatory and compliance, Commercialization challenges, Funding source loss
- Price in estimated range
- Earnings for 3 months up through Q1 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [24.50$, 92.35$]
- 2026-12-31 to 2027-12-31 estimated range: [9.55$, 40.39$]
Financial Metrics affecting the SPRB estimates:
- Negative: with PPE of -1.6 at the end of fiscal year the price was very high
- Negative: negative Operating cash flow
- Negative: negative Operating income
- Negative: negative Net income
- Positive: Investing cash flow per share per price, % of 0 > -0.60
- Negative: negative Industry operating cash flow (median)
Short-term SPRB quotes
Long-term SPRB plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $10.09MM | $4.91MM | $0.00MM |
| Operating Expenses | $62.08MM | $61.06MM | $36.51MM |
| Operating Income | $-51.99MM | $-56.15MM | $-36.51MM |
| Non-Operating Income | $4.07MM | $3.12MM | $-2.45MM |
| Interest Expense | $0.48MM | $0.31MM | $0.09MM |
| R&D Expense | $49.43MM | $46.42MM | $19.52MM |
| Income(Loss) | $-47.92MM | $-53.04MM | $-38.97MM |
| Net Income(Loss)* | $-47.92MM | $-53.04MM | $-38.97MM |
| Stockholders Equity | $76.51MM | $28.82MM | $42.52MM |
| Assets | $103.95MM | $45.21MM | $53.02MM |
| Operating Cash Flow | $-33.27MM | $-55.96MM | $-33.33MM |
| Capital expenditure | $0.01MM | $0.00MM | $0.00MM |
| Investing Cash Flow | $55.78MM | $0.00MM | $0.00MM |
| Financing Cash Flow | $49.14MM | $-1.62MM | $43.48MM |
| Earnings Per Share** | $-95.72 | $-98.87 | $-50.83 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.